| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | 0.26 | 5e-13 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | 0.25 | 3e-12 |
| mRNA | BRD-K14844214 | CTRPv2 | pan-cancer | AAC | 0.26 | 6e-12 |
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.21 | 4e-11 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.23 | 2e-10 |
| mRNA | TL-1-85 | GDSC1000 | pan-cancer | AAC | 0.18 | 2e-09 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.21 | 5e-09 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.2 | 2e-08 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.17 | 4e-07 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |